A detailed history of Great West Life Assurance CO transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Great West Life Assurance CO holds 4,050 shares of AKRO stock, worth $124,092. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,050
Previous 4,050 -0.0%
Holding current value
$124,092
Previous $95,000 22.11%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023

BUY
$41.19 - $52.25 $105,611 - $133,969
2,564 Added 172.54%
4,050 $205,000
Q4 2022

Feb 10, 2023

BUY
$33.44 - $54.8 $30,129 - $49,374
901 Added 154.02%
1,486 $82,000
Q3 2022

Nov 01, 2022

BUY
$10.15 - $34.05 $5,937 - $19,919
585 New
585 $20,000
Q2 2021

Aug 11, 2021

SELL
$24.81 - $32.35 $22,403 - $29,212
-903 Reduced 60.69%
585 $15,000
Q2 2020

Aug 17, 2020

BUY
$19.25 - $26.76 $28,644 - $39,818
1,488 New
1,488 $37,000

Others Institutions Holding AKRO

About Akero Therapeutics, Inc.


  • Ticker AKRO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,417,600
  • Market Cap $1.42B
  • Description
  • Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...
More about AKRO
Track This Portfolio

Track Great West Life Assurance CO Portfolio

Follow Great West Life Assurance CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Great West Life Assurance CO , based on Form 13F filings with the SEC.

News

Stay updated on Great West Life Assurance CO with notifications on news.